

Attorney Docket No.: 3745.234-US



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Efendic et al.

Serial No.: 09/754,723

Group Art Unit: 1614

Filed: January 4, 2001

Examiner: P. Duffy

Confirmation No: 3358

For: Use of a Peptide

# 14/C  
JMR  
REC'D  
MAY 12, 2003  
S/SS/03  
MAY 16, 2003  
TECH CENTER 1600  
PATENT

**AMENDMENT UNDER 37 C.F.R.1.116**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

This Amendment is submitted in response to the Office Action dated November 5, 2002 in which the Examiner finally rejected claims 15-20 of the above-captioned application. Reconsideration is respectfully requested in view of the following amendments and remarks.

**IN THE CLAIMS:**

Please amend the claims as follows:

15. (Amended) A method for treating type 2 diabetes, said method comprising administering to a patient in need of said treatment i) an effective amount of metformin via oral administration and ii) an effective amount of a GLP-1 related peptide via injection or infusion, where said GLP-1 related peptide is GLP-1 (7-37), GLP-1 (7-36) amide, an analogue of GLP-1 (7-37) or GLP-1 (7-36) amide, or a functional derivative thereof.

DO NOT ANNOTATE  
SIR 14/C  
2A/C